Skip to main content

CITADEL ADVISORS LLC

Position in TNGX — Tango Therapeutics, Inc.

CIK 1423053 MIAMI, FL

Position in TNGX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$3,753,529
+$2,407,873 QoQ
Shares Held
179,423
+18.1% QoQ
Ownership
0.124%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Sep 2021
17 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in TNGX Over Time

Shares Held

Position Value (USD)

Derivatives in TNGX

reported options exposure · as of Mar 31, 2026
CallValue
$1,010,436
CallShares
48,300
PutValue
$464,424
PutShares
22,200

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. TNGX ranks #152 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in TNGX

Export CSV
31 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $464,424 22,200
2026-03-31 $1,010,436 48,300
2026-03-31 $3,753,529 179,423
2025-12-31 $1,345,656 151,880
2025-12-31 $102,776 11,600
2025-06-30 $82,944 16,200
2025-06-30 $281,932 55,065
2025-03-31 $1,507 1,100
2025-03-31 $145,907 106,502
2024-12-31 $13,596 4,400
2024-12-31 $5,026,685 1,626,759
2024-12-31 $4,326 1,400
2024-09-30 $11,550 1,500
2024-09-30 $23,870 3,100
2024-09-30 $20,744,762 2,694,125
2024-06-30 $10,568,475 1,231,757
2024-06-30 $8,580 1,000
2024-06-30 $22,308 2,600
2024-03-31 $12,704 1,600
2024-03-31 $3,700,976 466,118
2024-03-31 $15,880 2,000
2023-12-31 $1,997,967 201,815
2023-12-31 $4,950 500
2023-06-30 $547,753 164,986
2023-03-31 $683,594 173,062
2022-12-31 $2,649,041 365,385
2022-09-30 $1,731,315 478,264
2022-06-30 $1,876,303 414,195
2022-03-31 $3,018,241 398,185
2021-12-31 $5,045,899 461,234
2021-09-30 $5,282,228 408,525